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Site I of antigenic domain 2 (AD-2) on human cytomegalovirus glycoprotein B (gB) is poorly immunogenic in both man and
mouse and knowledge about antibody repertoires reactive with this epitope is thus limited. Here we have characterized a
phage display-derived repertoire of antibody fragments specific for this epitope in terms of antigen recognition, fine-
specificity, and virus-neutralizing capacity. Our results show that the functional properties within a closely related repertoire
may differ widely and that the effectiveness of the members of the repertoire to neutralize the virus is determined by the
fine-specificity and kinetics of the interaction with the antigen. The half-life of the interaction between monomeric antibody
fragments and gB seems to be particularly critical for the neutralizing capacity. We also demonstrate that sequence variation
within gB allows virus variants to escape at least a part of the AD-2-specific neutralizing antibody repertoire, apparentlyKey Words: human cytomegalovirus; glycoprotein B; ant
INTRODUCTION
Human cytomegalovirus (HCMV) constitutes a serious
threat to congenitally infected newborns and immuno-
compromised individuals such as AIDS patients and
transplant recipients, while the infection in most cases is
asymptomatic in healthy individuals (Britt and Alford,
1996). A functional immune system thus seems to be
required for resistance to HCMV infection. However, the
virus has invented a multitude of ways of modulating the
host immune response (Loenen et al., 2001), which pre-
vent the immune system from eliminating the virus com-
pletely and allow it to establish latency. When the im-
mune defense of the host is compromised, the virus
becomes reactivated and may cause severe disease.
The humoral immune response against HCMV is di-
rected toward a number of proteins, among which gly-
coprotein B (gB) is particularly interesting due to its role
in the infection process and its prominent immunogenic-
ity. Glycoprotein B is a highly abundant component of the
envelope of virions, which mediates membrane penetra-
tion, cell-to-cell spread, and membrane fusion processes
(Navarro et al., 1993; Tugizov et al., 1994). It is also the
major target for neutralizing antibodies in humans (Britt
and Mach, 1996). Mature gB is derived from a glycosy-
lated precursor by proteolytical cleavage into an N-ter-
minal (gp116) and a C-terminal fragment (gp55), which
1 To whom correspondence and reprint requests should be addressed201epertoire; neutralization; AD-2.
form a disulfide-linked complex (Britt and Mach, 1996).
These complexes are further oligomerized and the gB
found in the membranes of infected cells and virions is a
homodimer of gp55–gp116 complexes (Britt and Vugler,
1992). The C-terminal fragment contains a linear anti-
genic region of more than 75 amino acids, antigenic
domain 1 (AD-1) (Utz et al., 1989; Wagner et al., 1992),
which is the immunodominant region of gB. Nearly all
infected individuals develop antibodies against this
structure (Schoppel et al., 1997). The N-terminal fragment
also contains an immunogenic region, antigenic domain
2 (AD-2), originally defined between residues 27 and 84
(Meyer et al., 1990). A subsequent study showed that this
region actually consists of two antibody-binding sites,
site I, between residues 68 and 77, and site II, between
residues 50 and 54 (Meyer et al., 1992). Both AD-1 and
site I of AD-2 give rise to potent virus neutralizing anti-
bodies, but the latter induces, in contrast to AD-1, anti-
bodies in only a minority of individuals infected with
HCMV (Ayata et al., 1994; Meyer et al., 1992; Navarro et
al., 1997; Schoppel et al., 1997).
Genetic analyses have revealed sequence variation
within several regions of gB, and specific genotypes
have been reported to be associated with different clin-
ical outcomes of HCMV infection (Rasmussen, 1999).
However, most of the reported sequence variation lies
outside of the immunogenic regions, which suggests
important roles of these regions in the biology of HCMV
and makes them attractive targets for antibody-basedwithout preventing antibody binding to the epitope. © 2002
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ably greater sequence variation has been found within
site II of AD-2 (Chou and Dennison, 1991; Lehner et al.,
1991; Meyer-Ko¨nig et al., 1998; Roy et al., 1993; Shiu et al.,
1994).
Due to its immunogenicity and the fact that several in
vitro studies have demonstrated neutralization of HCMV
infectivity using antibodies against it (Britt, 1984; Kari et
al., 1986; Navarro et al., 1993; Ohlin et al., 1993), gB has
been the focus of intense studies aimed at preventing or
treating HCMV infection. For instance, vaccination trials
have been performed with recombinant, soluble gB and
a canarypox-gB recombinant, and both have demon-
strated induction of a neutralizing antibody response
(Plotkin, 2001). However, to date little is known about
antibody repertoires recognizing the major protective
epitopes on HCMV and which possibilities the virus has
to escape the neutralizing activity of antibodies that de-
velop as a consequence of infection or vaccination.
In this study we have characterized a human antibody
repertoire specific for site I of AD-2 representing different
modes by which the humoral immune response may
recognize this epitope. This repertoire has been ob-
tained by selection of single-chain variable region frag-
ment (scFv) variants recognizing AD-2 from phage-dis-
played libraries (Lantto et al., 2002b). The libraries were
created by genetic engineering of one of the two existing
human antibodies specific for this epitope, ITC88 (Ohlin
et al., 1993), in a manner similar to the one used by the
immune system to evolve antibodies in the germinal
center reaction. Using these in vitro evolved antibody
fragments, we have assessed the fine-specificity and
binding kinetics of such an AD-2-specific antibody rep-
ertoire and defined characteristics of scFv variants that
were able to mediate virus neutralization. We have also
investigated the effect of rarely occurring sequence vari-
ation within site I of AD-2 on the neutralizing capacity of
the antibody repertoire.
RESULTS
The in vitro evolved AD-2-specific repertoire
Using combinatorial library technology and phage dis-
play, a set of clonally related antibody fragments recog-
nizing AD-2 on HCMV gB has been developed (Lantto et
al., 2002b). As shown in Fig. 1, these clones are highly
similar in sequence and differ from the original AE11F
sequence at a maximum of 12 residues. Due to the
nature of the differences and the way they were ob-
tained, these clones may be thought of as a repertoire of
antibodies that has developed as a consequence of
somatic evolution of a single sequence.
Virus neutralizing capacity of the AD-2-specific scFv
We have shown in a previous study that the AE11F
clone is unable to neutralize the AD169 laboratory strain
of HCMV as monomeric scFv, while dimeric scFv or
monomeric scFv which have been dimerized by the use
of anti-FLAG antibody do neutralize the virus (Lantto et
al., 2002a). To define the virus neutralizing potential of a
clonally related antibody repertoire, we here determined
the ability of the variant AD-2-specific scFv to neutralize
the AD169 strain. The AE11F, D3-3(2)/11, F3c10/2, and
F3c10/8 scFv were tested after dimerization by anti-FLAG
antibody or as spontaneously dimerized preparations.
The monomeric forms of the H3b/31, H3c/12, H3c/22, and
AE11F/3-20L1 scFv were similarly tested after dimeriza-
tion by anti-FLAG antibody. The assay showed that three
of the clones, H3b/31, H3c/12, and AE11F/3-20L1, were
unable to neutralize this strain even at the highest con-
centration tested, i.e., 10 g/ml (Table 1). In accordance
with the previous study (Lantto et al., 2002a), none of the
variant clones were able to neutralize the virus as mo-
nomeric scFv (data not shown).
Antigen binding by the AD-2-specific repertoire
We have previously established that all of the antibody
fragments studied here recognize a short AD-2-mimick-
ing peptide, although with different affinities (Lantto et
al., 2002b). As this peptide probably only partly mimicks
the epitope found on gB, we analyzed the binding of the
different clones to intact gB, both as it is found in HCMV-
infected cells and as recombinant protein coated to a
BIAcore chip, to address the reason for the differences in
neutralizing capacity among the scFv clones. The bind-
ing to natural gB was assessed by indirect immunofluo-
rescence studies using monomeric scFv and human
fibroblasts infected with the AD169 strain. All of the
neutralizing clones had titration endpoints between 0.25
and 0.5 g/ml, while the nonneutralizing clones H3b/31,
H3c/12, and AE11F/3-20L1 only displayed weak binding
to the infected cells even at the highest concentration
tested, i.e., 5 g/ml (Table 1). The titration endpoints
were similar for the monomeric and the dimeric forms of
the scFv that were tested in both formats (data not
shown).
To further substantiate the relationship between antigen
binding and neutralizing capacity, the kinetics of the inter-
action between the scFv and the intact, extracellular part of
recombinant gB was assessed by the use of the BIAcore
technology. This recombinant gB molecule is derived from
the Towne strain of HCMV (Spaete, 1991), but the Towne
and AD169 strains are identical in the parts of the se-
quences corresponding to site I of AD-2 (Cranage et al.,
1986; Spaete et al., 1988), and both strains are neutralized
just as effectively by the ITC88 antibody (Manuel, 1996). As
shown in Table 1, there were large differences in the half-
lives of the different scFv clones on this antigen. Impor-
tantly, all of the nonneutralizing clones showed a much
more rapid dissociation from the intact gB than the neutral-
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izing clones, which all displayed half-lives longer than 1 h
on this antigen (Table 1).
Fine-specificity of antigen recognition
To further dissect the differences in antigen binding
and virus-neutralizing capacity within the repertoire, the
fine-specificity of the different clones was determined by
an ORIGEN-based inhibition assay using a set of ala-
nine-scanned peptides corresponding to site I of AD-2
and adjacent residues. The observed overall reactivity
pattern with these peptides was similar for all of the scFv
clones. Certain positions totally abrogated the inhibiting
capacity of the peptide when replaced by an alanine,
while others seemed not to affect the binding to the scFv
to any greater extent. As shown for the parent AE11F
scFv in Fig. 2, positions that were critical for the recog-
nition of the peptides included Y72, T75, L76, and Y78.
Titration of the inhibiting peptides revealed further subtle
differences in fine-specificity among the different scFv
clones. For instance, the T74 3 A substitution, which is
also found in the A8 clinical isolate of HCMV (Manuel,
1996), was differently recognized by the members of the
repertoire. In particular, the D3-3(2)/11 and H3c/22
clones were less affected by this sequence modification
than the other clones, including the original AE11F scFv
(Fig. 3A). Furthermore, all of the nonneutralizing clones
were less inhibited by the D80 3 A substituted peptide
than the other clones (Fig. 3B, and data not shown). For
a comparison, all of the tested clones except AE11F/3-
20L1, which displayed a much reduced affinity for the
peptide antigen (data not shown), were approximately
equally inhibited by the consensus peptide (Fig. 3).
FIG. 1. Alignment of the deduced amino acid sequences of scFv clones specific for AD-2. Sequences are aligned and numbered according to the
IMGT unique numbering for V-DOMAIN (Lefranc, 2001) except for the first complementarity determining regions (CDR) of the light chains, which are
aligned according to sequence homology to facilitate comparison. Gaps are indicated by dashes. Amino acids and nucleotides that are part of the
CDR, as defined in IMGT (Lefranc, 2001), are indicated by shaded boxes. The (Gly)4Ser linker and the C-terminal FLAG epitope are indicated by lighter
print. The nucleotide sequences have been deposited in GenBank. Previously published scFv clones (Lantto et al., 2002b) are available under
Accession Nos. AF443427–AF443432 and the AE11F/3-20L1 clone under Accession No. AF492001.
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The results with the T74 3 A substituted peptide were
confirmed by BIAcore measurements. All of the tested
clones displayed a much faster dissociation from the
substituted peptide than the consensus peptide, but the
increase in dissociation rate varied greatly among the
clones. The two clones that were most effectively inhib-
ited by the T74 3 A substituted peptide in the ORIGEN-
based assay, D3-3(2)/11 and H3c/22 (Fig. 3A), were also
the ones with the lowest dissociation rates from the
substituted peptide. These clones displayed half-lives of
approximately 3 min on this substituted peptide, while all
the other tested clones had half-lives below 1 min (data
not shown).
Recognition and neutralization of a virus strain with a
substitution within site I of AD-2
In light of the observed differences in fine-specificity
within the scFv repertoire, especially with the potentially
biologically significant T74 3 A mutation, we decided to
investigate the effect of sequence variation within gB on
the virus recognition and neutralizing capacity of some of
the scFv clones. Indirect immunofluorescence studies
with the A8 clinical isolate showed that the tested scFv
clones bound to this virus variant with titration endpoints
between 0.25 and 0.5 g/ml (Table 2), i.e., approximately
equally well as to the AD169 strain. The plaque reduction
assay showed, however, that the neutralizing capacity of
the scFv clones differed with this isolate. As shown in
Table 2, the dimerized AE11F and D3-3(2)/11 scFv neu-
tralized the A8 strain with similar or lower EC50 values as
shown for the AD169 strain. The dimerized F3c10/2 scFv,
on the other hand, did not show any signs of neutraliza-
tion with this strain even at the highest concentration
tested, i.e., 4 g/ml (Table 2), despite the fact that it
bound to infected cells as well as the other scFv did.
Thus, the A8 clinical isolate of HCMV escapes neutral-
ization by a part of this AD-2-specific antibody repertoire
seemingly without eliminating antibody binding to the
epitope.
DISCUSSION
In this study we have characterized a repertoire of
scFv specific for site I of AD-2 on HCMV gB in terms of
fine-specificity, reactivity with gB, and virus neutralizing
capacity. This epitope elicits potent neutralizing antibod-
ies, but is poorly immunogenic in humans as well as in
mice, and thus little is known about antibody repertoires
recognizing it. We have therefore created a repertoire of
antibody fragments reactive with peptides that mimick
this epitope by in vitro evolution and phage display-
based selections. The scFv clones studied here are
more than 95% identical in amino acid sequence and
may be regarded as a repertoire of antibodies, which has
arisen from a single clone through the natural process of
somatic hypermutation. In fact, most of the amino acid
substitutions can be created by single base point muta-
tions from the gene encoding AE11F. Even a variant such
as the AE11F/3-20L1 clone, which carries an insertion in
CDRL1, can be produced by somatic hypermutation as
both insertions and deletions are part of this naturally
occurring process (Lantto and Ohlin, 2002; Wilson et al.,
1998).
FIG. 2. Reactivity profile of the monomeric AE11F scFv with alanine-
scanned peptides covering site I of AD-2 on gB as determined by using
the ORIGEN technology. Each bar represents a peptide with an alanine
substitution at the indicated position. Numbering is according to the
AD169 gB sequence (Cranage et al., 1986). The dash indicates the
negative-control peptide. The reactivity was defined as a percentage of
the electrochemiluminescence signal obtained without any inhibiting
peptide. Experiments were performed in duplicate using 10 g/ml of
inhibiting peptide.
TABLE 1
Comparison of the Neutralization of HCMV Strain AD169 and the
Binding to AD169-Infected Cells and Recombinant gB by Monomeric
AD-2-Specific scFv
Clone
EC50
(g/ml)a
Titration endpoint
(g/ml)b
Half-life
(min)c
AE11F 0.5 0.25 120
D3-3(2)/11 1.0 0.5 77
F3c10/2 1.0 0.5 120
F3c10/8 1.1 0.5 77
H3b/31 10 5 7
H3c/12 10 5 9
H3c/22 2.5 0.5 77
AE11F/3-20L1 10 5 14
a The EC50 value is the concentration of scFv required to give 50%
plaque reduction as calculated using the Reed–Muench method
(Thorpe et al., 1987). The reported values are for monomeric scFv
dimerized by anti-FLAG antibody. The results were identical for the
tested spontaneously dimerized scFv.
b The titration endpoint is the lowest concentration of scFv that gives
rise to visible staining of HCMV-infected cells as determined by indirect
immunofluorescence.
c Half-lives were determined by BIAcore measurements. Each value
is the average of at least three different measurements.
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Despite the close relatedness of the antibody frag-
ments in this repertoire, the results from this study show
that their functional properties differ widely. Due to the
lack of antibodies against AD-2, this phenomenon has
not been recognized before. Why is it then so that a
selection of closely related antibodies differ widely in
their antigen recognition and virus-neutralizing potential?
We have previously shown that divalent binding of the
AE11F scFv is required for virus neutralization via AD-2
(Lantto et al., 2002a), indicating that either sterical hin-
drance through the larger size of dimeric (or dimerized)
scFv or crosslinking of gB may be the mechanism re-
sponsible for the neutralization. The present study sup-
ports this observation as none of the variant scFv were
able to neutralize the virus as monomers either, but it
also provides additional insights into the neutralization
process. It seems clear that another very important factor
for the neutralization of HCMV via site I of AD-2 on gB is
the half-life of the scFv on the viral envelope. The BIA-
core studies showed that the nonneutralizing AD-2-spe-
cific scFv clones dissociated much faster than the neu-
tralizing clones from the recombinant gB (Table 1). This is
in agreement with the occupancy model by Burton et al.
(2001), according to which neutralization occurs when a
sufficient number of sites on the viral particle are occu-
pied by antibodies, thereby rendering the virus unable to
infect its target cell. As indicated by the extended half-
lives of the neutralizing scFv clones on the recombinant
gB, they are probably also able to remain on the virus
particles for a long-enough period of time to prevent
infection from occurring.
One thing all of the neutralizing clones have in com-
mon is the presence of two glycines at positions 30 and
31 in the first CDR of the light chain (Fig. 1). These two
residues are found in the sequence of the original ITC88
antibody (Ohlin et al., 1996), probably as a result of
somatic mutation events, and most of the previously
selected AD-2-specific scFv clones also carry this se-
FIG. 3. Inhibition of binding of monomeric scFv to streptavidin-bound AD-2 consensus peptide by (A) nonbiotinylated T74 3 A substituted peptide
(F) or (B) nonbiotinylated D80 3 A substituted peptide () as determined by using the ORIGEN technology (see legend to Fig. 2). Both substituted
peptides are compared to the nonbiotinylated consensus peptide (Œ). Experiments for all data points were performed in duplicate.
TABLE 2
Comparison of the Neutralization of HCMV Clinical Isolate A8 and
Binding to A8-Infected Cells by Monomeric AD-2-Specific scFv
Clone
EC50
(g/ml)a
Titration endpoint
(g/ml)b
A11F 0.5 0.25
D3-3(2)/11 0.6 0.5
F3c10/2 4 0.5
a The EC50 value is the concentration of scFv required to give 50%
plaque reduction as calculated using the Reed–Muench method
(Thorpe et al., 1987). The reported values are for monomeric scFv
dimerized by anti-FLAG antibody. The results were identical for the
spontaneously dimerized scFv.
b The titration endpoint is the lowest concentration of scFv that gives
rise to visible staining of HCMV-infected cells as determined by indirect
immunofluorescence.
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quence motif (Lantto et al., 2002b). The fast-dissociating,
and thus nonneutralizing, H3b/31 and H3c/12 clones
carry two serines, which are also found in the IGKV3-11
germline gene the ITC88 light chain originates from, at
these positions. The similarly nonneutralizing AE11F/3-
20L1 clone carries a closely related motif, which in-
cludes an additional serine residue. In other words, it
seems as though antibodies originating from the
IGKV3-11 germline gene and related genes require sub-
stitutions at certain positions to gain the high-affinity
character. We have previously demonstrated that a mu-
tation at position 34 in the first CDR of the heavy chain
seems to be essential for effective antigen recognition as
mutation of this residue to the germline-encoded amino
acid decreases the half-life of the scFv on gB 40-fold
(Lantto et al., 2002b). The fact that multiple mutations
seem to be required for high-affinity recognition of site I
of AD-2 may in some part explain the poor immunoge-
nicity and the slow development of antibodies against
this epitope (Schoppel et al., 1997).
The fine-specificity patterns of the original antibody,
the AE11 scFv, and chain-shuffled variants of this have
been characterized using overlapping synthetic peptides
(Ohlin et al., 1993, 1996). In this study we took the inves-
tigation one step further and analyzed the effect of point
mutations within the epitope using alanine-scanned pep-
tides. The overall reactivity observed here was in accor-
dance with the previous results with the original antibody
and the scFv derived from this, but this analysis also
revealed the importance of the sidechains of individual
residues within the stretch of amino acids representing
AD-2 and adjacent regions. One of the most interesting
findings was the varying recognition of the T74 3 A
substitution (Fig. 3A), as this mutation is also found in a
clinical isolate of HCMV (Manuel, 1996). Although the
differing recognition of this mutation was not reflected in
the immunofluorescence assay with the A8 clinical iso-
late, the scFv clones differed widely in their capacity to
neutralize this strain (Table 2). The T74 3 A mutation is
most likely not the reason for this behavior though, since
the F3c10/2 scFv had a half-life on the T74 3 A substi-
tuted peptide similar to that of the rest of the repertoire,
including the original AE11F scFv, and also bound to
cells infected with the A8 strain with a similar titration
endpoint as the D3-3(2)/11 scFv. The A8 strain carries
several other mutations within the gB sequence (Manuel,
1996) and any one of these may affect the interactions
with the D3-3(2)/11 and F3c10/2 scFv either directly or via
conformational changes induced in the epitope. Further-
more, as the footprint of an antibody-binding site on the
surface of a protein is clearly larger than the buried
surface area of interaction between an antibody and a
peptide [600–900 Å2 vs 460–580 Å2 (Braden and Poljak,
1995; Dokurno et al., 1998; Webster et al., 1994)], it is
evident that there are additional points of contact be-
tween the antibodies specific for this epitope and the
protein antigen besides the residues corresponding to
the peptide. This is also evidenced by the much slower
dissociation of the scFv from intact gB as compared to
the peptide antigen (Lantto et al., 2002a,b).
The fact that the F3c10/2 scFv binds rather well to gB
as expressed by cells infected with the A8 isolate, yet
does not neutralize this virus strain, may seem contra-
dictory to the previously cited occupancy model (Burton
et al., 2001). One explanation for this discrepancy, which
is also suggested by Burton et al., (2001), may be that the
F3c10/2 scFv does not bind well to the properly folded
form of the gB displayed on the surface of the infective
particles of the A8 isolate, but is still able to bind to the
epitope presented by denatured gB found in fixed cells or
by not fully processed gB, which is fairly abundant in
infected cells (Britt and Vugler, 1989). The scFv may
accordingly not occupy enough sites on the virion for
neutralization to occur despite the apparent binding to
infected cells. However, there has been at least one
report of an antibody that coats viral particles without
neutralizing infectivity (Flamand et al., 1993), indicating
that it cannot be excluded that the F3c10/2 scFv also
binds to correctly folded gB on infective particles. Fur-
thermore, as both of the known human antibodies that
bind to gB via site I of AD-2 do so without preventing the
virus from binding to the surface of the target cells (D.
Gicklhorn, M. Eickmann, A. Waltermann, M. Ohlin, and K.
Radsak, unpublished data; Ohizumi et al., 1992), the
increase in the concentration of interacting molecules
due to the close apposition of the virus and cell mem-
branes may also be related to these effects. Irrespective
of the reason for the observed discrepancy or the pos-
sible unimportance of the T74 3 A mutation, the results
demonstrate that HCMV variants that can escape neu-
tralization by at least a part of the otherwise neutralizing
AD-2 specific repertoire may arise through mutations
within the gB sequence.
Another important observation from the fine-specificity
study was the fact that the nonneutralizing clones carry-
ing the unmutated motif in the first CDR of the light chain
all displayed an increased dependency for the aspartate
at the position corresponding to residue 80 of gB in
comparison to the rest of the clones. This residue is
actually not part of the epitope required for antigen rec-
ognition by the original ITC88 antibody as determined by
inhibition with overlapping peptides (Ohlin et al., 1993),
and the AE11F scFv clone consequently showed identi-
cal inhibition with the D80 3 A substituted peptide as
with the consensus peptide (Fig. 3B). A similar correla-
tion between fine-specificity and incapability of virus
neutralization has been observed with in vivo derived
antibody repertoires. Affinity-purified antibodies from hu-
man as well as rabbit sera, which displayed a specificity
that mapped toward the C-terminus of the consensus
peptide sequence corresponding to amino acids 67–86
of gB, showed no neutralizing activity with HCMV strain
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AD169 (Silvestri et al., 1993). Since the sequences of the
AD-2-specific antibodies in these sera are unknown, one
can only speculate about the nature of the antibodies
responsible for this behavior. As discussed before, these
possibly germline-encoded, nonneutralizing antibodies
may bind well only to epitopes presented by peptide
antigens or immature/misfolded gB found in infected
cells, but not to the epitope presented by gB on infective
particles. However, as shown above, it is quite possible
that AD-2 gives rise to antibodies, in vivo as well as in
vitro, that bind to the epitope as found on infective gB
molecules, but are unable to neutralize virus infectivity.
The corresponding observation has in fact been made
with various unrelated antibodies against AD-1, the other
major protective epitope on gB (Speckner et al., 1999).
The low-affinity antibodies described here may not seem
a major problem as it is commonly believed that high-
affinity clones outcompete lower affinity clones during
the immune response. However, it has been shown that
affinity maturation in germinal centers appears to be
local, i.e., that low-affinity clones may very well coexist
with high-affinity clones (Dal Porto et al., 1998 and refer-
ences therein). The presence of these epitope-binding,
but nonneutralizing, antibodies may seriously affect the
outcome of both naturally occurring infections and vac-
cinations if the interaction with the epitope is strong
enough, as they may compete with the neutralizing an-
tibodies and thus decrease the protective effect of the
latter. Furthermore, the lack of virus-neutralizing activity
of parts of this and other anti-gB repertoires may explain,
at least partly, the poor correlation of gB-specific anti-
body titers and virus neutralization occasionally ob-
served in vivo (Kropff et al., 1993; Marshall et al., 2000).
In conclusion, we have shown that the neutralizing
potential of the members of an AD-2-specific antibody
repertoire depends on the fine-specificity and reaction
rate kinetics of the interaction with the antigen. This
implies that the quality of the antibodies formed against
this epitope in response to virus infection and immuni-
zation will be an important parameter to review when
determining the ability of such immune responses to
actually protect against disease. Our results also give
further insight into the ability of HCMV to escape the
AD-2-specific neutralizing antibody response as we
show here that site I of AD-2 may elicit both neutralizing
and nonneutralizing antibodies, and that sequence vari-
ation within gB may render otherwise neutralizing AD-2-
specific antibodies ineffective, probably without eliminat-
ing antibody binding to the epitope. The combination of
the neutralizing and nonneutralizing antibodies most
likely reduces the protective potential of the antibody
response and may have important consequences for the
efficacy of both passive immunotherapy and gB subunit
vaccines.
MATERIALS AND METHODS
Antibodies and antigens
The original AD-2-specific antibody (ITC88) and its
scFv format (AE11) have been described previously
(Ohlin et al., 1993, 1996). The variant scFv studied here
(see Fig. 1) have been selected from phage-displayed
libraries (Lantto et al., 2002b), which were constructed
using the CDR-shuffling approach (Jirholt et al., 1998) on
AE11. A number of selected clones and the original scFv
(called AE11F in this format) have subsequently been
produced in Pichia pastoris with C-terminal FLAG se-
quences and purified in monomeric and dimeric form by
gel filtration (Lantto et al., 2002b).
Peptides mimicking AD-2 have previously been used
for the library selections (Lantto et al., 2002b) and were
now used for the characterization of the scFv clones.
Both biotinylated and nonbiotinylated 15-meric peptides
corresponding to the consensus AD-2 sequence
[ANETIYNTTLKYGDV (Cranage et al., 1986)] as well as a
set of unbiotinylated, alanine-scanned (Cunningham and
Wells, 1989) peptides of identical length were used. The
peptide carrying the T74 3 A substitution (ANETIYN-
ATLKYGDV) was also used in its biotinylated form. A
decameric peptide containing residues known to be im-
portant for the interaction with AE11 (Ohlin et al., 1996) in
scrambled order (YTLETYINKT) was used as a negative
control. The biotinylated peptides were purchased from
Genosys Biotechnologies Inc. (Cambridge, U.K.) and
MedProbe AS (Oslo, Norway), while the nonbiotinylated
peptides were kindly provided by Dr. Vivi-Anne Sundqvist
(Karolinska Institutet, Stockholm, Sweden). Recombinant
gB produced in Chinese hamster ovary cells (Spaete,
1991) was kindly provided by Claude Me´ric (Aventis Pas-
teur, Marcy-l’Etoile, France).
Virus strains
HCMV strains have previously been isolated from the
blood of renal transplant recipients and AIDS patients
and sequenced across the protective epitopes of the gB
gene (Roy et al., 1993). Although there was considerable
nucleotide variation among the strains, most strains did
not carry substitutions that resulted in codon changes
within site I of AD-2 (Manuel, 1996). The sequence of the
A8 isolate of HCMV differs from the laboratory reference
strain AD169 at three amino acid positions within or in
the immediate vicinity of site I [A67 3 V, E69 3 V, and
T74 3 A; amino acid numbering according to the AD169
gB sequence (Cranage et al., 1986)]. The A8 isolate was
propagated for less than 10 passages in human embry-
onic lung fibroblasts and cell-free virus was harvested
from the supernatant after clarification by centrifugation.
The virus titer was measured by plaque assay (Roy and
Grundy, 1992). The AD169 (passage 94) laboratory refer-
ence strain (European Collection of Animal Cell Cultures,
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Salisbury, Wiltshire, U.K.) was propagated and assayed
similarly.
Neutralization assays
Antibody neutralization assays were performed essen-
tially as described previously (Roy and Grundy, 1992).
Monomeric scFv antibody fragments were dimerized by
incubation in minimal essential medium supplemented
with 2% fetal calf serum for 30 min at 37°C with anti-
FLAG M2 antibody (Sigma Chemical Co., St. Louis, MO)
at a molar ratio of 2:1. Serial dilutions of monomeric or
dimeric scFv were incubated for 60 min at 37°C with the
concentration of virus required to produce 50–100 viral
plaques per well. The various dilutions were then inoc-
ulated in triplicate for 60 min onto fibroblast monolayers.
The cell monolayers were washed twice and a 2% meth-
ylcellulose overlay was added. After 12 days incubation
at 37°C in 5% CO2, the cells were fixed in 10% v/v
formalin and stained with 0.03% methylene blue. The
numbers of viral plaques per well were counted and the
mean number of PFU per milliliter was calculated for
each dilution of a given antibody. The effective concen-
tration giving 50% plaque reduction (EC50) was calculated
using the Reed–Muench method (Thorpe et al., 1987).
Immunofluorescence
Human embryonic lung fibroblasts were infected with
HCMV for 4 days, after which the cells were harvested,
adhered to multiwell slides, dried, and fixed in acetone:
PBS (66:34) for 20 min at 4°C. The slides were incubated
with dimeric or monomeric scFv at different concentra-
tions and the binding of the scFv was detected using
anti-FLAG M2 antibody (Sigma) followed by FITC-conju-
gated F(ab)2 preparation of sheep anti-mouse IgG anti-
body (Sigma). The slides were mounted using Citifluor
(Citifluor Ltd., Canterbury, U.K.) and viewed under a UV
microscope to determine the titration endpoints (i.e., the
lowest concentrations that produced visible staining).
Uninfected fibroblasts were used similarly as a negative
control.
Determination of fine-specificity and reaction rate
kinetics
The ORIGEN technology (M-SERIES M8 Analyzer,
IGEN International Inc., Gaithersburg, MD) was used to
determine the fine-specificity of the different scFv clones.
The analysis was performed essentially as the previ-
ously described ORIGEN analysis (Lantto et al., 2002b)
except that purified monomers of the scFv were used
instead of expression supernatants and nonbiotinylated
alanine-scanned peptides were added to block the inter-
action with the streptavidin-bound peptide.
The binding of the scFv to the consensus peptide, the
T74 3 A substituted peptide, and the intact, extracellular
part of gB was analyzed using the BIAcore technology
(BIAcore AB, Uppsala, Sweden). The antigens were im-
mobilized onto a CM5 sensor chip (BIAcore AB) either
through direct coupling (gB) using the Amine Coupling
Kit (Biacore AB) or through binding to similarly immobi-
lized streptavidin (Sigma) (biotinylated peptide antigens).
The binding of the scFv was recorded at a flow rate of 20
l/min, and the reaction rate kinetics, including the half-
life of the interaction, were calculated using the pre-
defined 1:1 (Langmuir) association and dissociation
models in the BIAevaluation 3.0 software (BIAcore AB).
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